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Interleukin-8 (neutrophil-activating factor; NAP-i) has been crystallized by the vapour diffusion technique to give single crystals suitable for three- 
dimensional structural study at a resolution higher than 2.4 A. The crystals belong to the space group P3,21 or P3=21 and have unit cell dimensions 
a=b=40.9A,c=90.3A. 
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1. INTRODUCTION 2. EXPERIMENTAL 
Interleukin-8 (IL-S) is a relatively newly-discovered 
inflammatory peptide which was isolated almost 
simultaneously by several groups as a secreted product 
of endotoxin-stimulated monocytes, and the peptide 
therefore has several names, including neutrophil- 
activating factor (NAF) [ 11, monocyte-derived neutro- 
Phil-activating peptide (MONAP) [2], monocyte-der- 
ived neutrophil chemotactic factor (MDNCF) [3], 
granulocyte-chemotactic peptide (GCP) [4] and 
monocyte-derived chemotaxin (MOC) [5]. 
We have produced the 72 amino acid form of IL-8 as a recombi- 
nant protein, by expression of a synthetic gene in E. coli[lO]. The 
purity and homogeneity of this product were sufficient for crystalli- 
zation studies. 
Interleukin-8 was stored in 50 mM 2-morpholinoethanesulfonic 
acid (Mes) (Fluka), pH 6.5, 3 mM sodium azide (NaNI) and 300 mM 
sodium chloride (NaCl) at 2.9 mg/ml. For crystallization the protein 
was concentrated to 20 mg/ml using an Amicon concentration cell 
8010, YM2 (diameter 25 mm). Using the hanging drop, vapor diffu- 
sion method [18], concentrated protein solution (20 ,ul) was mixed 
with the precipitating solution (l-3 ~1) and equilibrated against a 0.5 
ml chamber of precipitating solution. 
It has subsequently been shown that many cell types 
other than monocytes can produce large quantities of 
11-8 or IL-8 mRNA, in response to stimulation with en- 
dotoxin, IL-l or tumour necrosis factor (TNF) [ 1,6-g]. 
The major form of IL-8 produced by monocytes is 72 
amino acids in length and has a molecular mass of ap- 
proximately 8.4 kDa (approx. 70% is this form), 
although both longer and shorter forms are present in 
stimulated monocyte supernatants [lo]. However, 
Gimbrone et al. [ 1 I] have reported that endothelial cells 
produce a 77 amino acid molecule as their major form. 
Crystallization conditions for IL-8 were initially screened at 4°C 
over 50 different combinations of salt, pH and precipitant. Of these, 
the following combinations yielded single crystals: 
(1) 30%. 35%. 40% (w/w) polyethylene glycol (PEG) 20000 
(Fluka), 50 mM Mes, pH 6.5, 300 mM NaCl, 3 mM NaN3; 
(2) 30%, 35%, 40% (w/w) PEG 8000, 50 mM Mes, pH 6.5, 300 
mM NaCl, 3 mM NaN3; 
(3) 40% (w/w) PEG 6000, 50 mM Mes, pH 6.5, 300 mM NaCl, 3 
mM NaNs. 
The activities of IL-8 are not limited to the effects on 
neutrophils (PMN) by which it was initially identified. 
It activates PMN to degranulate and exhibit respiratory 
burst [12,13] and is chemotactic for PMN and lym- 
phocytes in vitro and in vivo [2,4,10,14]. Further ac- 
tivities include triggering of histamine and leukotriene 
release from IL-3-primed basophils [ 151, spasmogenic 
activity on airway smooth muscle [16], and effects on 
PMN adherence to endothelial cells [11,17]. 
Crystals grew as rhomboids within 10 days to a final size of 
0.5 x 0.4 x 0.4 mm3 in the first two sets of conditions and were slight- 
ly smaller with PEG 6000 (Fig. 1). For diffraction studies, crystals 
were mounted in 1 .O mm diameter glass capillaries and were stable in 
the X-ray beam for at least 24 h so that a full data set could usually 
be produced using one crystal. 
3. RESULTS AND DISCUSSION 
Correspondence address: M. Auer, Sandoz Forschunginstitut 
Ges.m.b.H., Brunnerstrasse 59, A-1235 Wien, Austria 
A native data set to 2.4 A resolution was collected on 
a fast area detector using CuK,-radiation (40 kV, 70 
mA) produced by a rotating anode X-ray generator 
(FR571). Indexing by the ENDEX program available in 
MADNES [19] and subsequent refinement (fixing 
CY =p= 90’) using 250 reflections gave a cell with 
a=40.86 A, b=40.87 A, c=!90.26 A and y= 120.03’. 
The data were then processed using COLLECT and 
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Fig. 1. Crystals of interleukin-8 expressed in E. coli. 
PROCOR [20] (11249 reflections) and merged in 
AGROVATA (CCP4-package) using all possible point- 
groups containing one 3-fold axis. Point group 321 
yielded R,,, = 3.4% (on intensities) for 10626 measure- 
ments (comprising samples of all symmetry equivalent 
reflections) of 3099 independent reflections (no rejec- 
tions). X-Ray precession photographs subsequently 
confirmed the point group and fixed the space-group at 
P3i21 or P3221. The unit cell volume is 130 800 A3. 
One chain of molecular mass = 8386 Da per asym- 
metric unit gives VIM = 2.60 A3/Da which is within the 
normal range for protein crystals [21]. Heavy atom 
derivative data sets have been collected and are current- 
ly under analysis. 
Although the solution structure of the interleukin-8 
dimer has been solved recently by nuclear magnetic 
resonance spectroscopy and hybrid distance geometry- 
dynamical simulated annealing calculations [22] and 
was shown to consist of two antiparallel cr-helices lying 
on top of a six-stranded antiparallel P-sheet platform, 
there are 3 main reasons for a determination of the 
crystal structure of IL-K 
Firstly, it will be important to see whether there are 
major differences between the crystal structure of the 
protein and its conformation in solution. Secondly, the 
72 amino acid form of the protein used for our crystal- 
lographic study is the basis of an extended mutagenesis 
programme at Sandoz intended to define the minimum 
structure required for full activity. Nine different 
mutants are now available [23] and results from bio- 
logical test systems show marked variation in activity. 
Crystallization experiments with the most interesting 
derivatives are in progress. Lastly, the relationship be- 
tween the biological function of these mutants and their 
precise structure, especially of the two symmetry- 
related helices could yield important information for 
the design of potential IL-8 inhibitors. 
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